Table of Contents
Toxic shock syndrome can be defined as an acute illness caused by toxin-producing bacteria. It is a multi-system disease that presents with organ failure in addition to fever, rash, hypotension, and skin manifestations.
Toxic shock syndrome is caused by toxin-producing strains of staphylococcus aureus and streptococcus.
Toxic shock syndrome is uncommon in children younger than 10 years for obscure reasons. One of the most common causes of toxic shock syndrome was the use of tampons in menstruating adolescent girls. Tampons must be changed more often so they are less likely to cause Staphylococcus aureus bacterial growth and toxic shock syndrome. The current incidence of toxic shock syndrome related to the use of tampons in female adolescents and young adults is approximately 0.5 per 100,000.
50% of cases are from tampons (all S aureus), especially super-absorbent tampons.
Nowadays, the incidence of toxic shock syndrome related to tampon use is almost equal to the incidence not related to tampon use. One particular group of children at risk of developing toxic shock syndrome are those who are admitted to the burns unit due to skin burns. Approximately, 10% of these children might experience toxic shock syndrome. Another common cause of toxic shock syndrome in children is post-operative complications. Approximately, 16 in every 100,000 children who undergo an ear, nose, or throat surgery will develop toxic shock syndrome.
Children are also at risk of developing streptococcal toxic shock syndrome. Group A streptococcus is responsible for approximately 4 in every 100,000 general population cases of toxic shock syndrome per year. While streptococcal toxic shock syndrome is more common in the elderly, children aged younger than 2 years are at a particularly increased risk.
While children might develop streptococcal toxic shock syndrome, the mortality rate is usually lower than it is in adults. The mortality rate of streptococcal toxic shock syndrome in children is estimated at 5%.
Pathophysiology of Toxic Shock Syndrome in Children
Toxic shock syndrome is most likely an immune-mediated disorder that is activated by a superantigen. This superantigen is most likely a toxin produced by certain strains of Staphylococcus aureus.
The most commonly produced toxins responsible for staphylococcal toxic shock syndrome in children are:
- Toxic shock syndrome toxin-1 (TSST-1) which is found in 75% of the patients.
- Enterotoxin-b which is found in approximately 23% of the patients with toxic shock syndrome.
- Enterotoxin-c which is found in only 2% of the patients.
Staphylococcus aureus strains that produce TSST-1 are more common in the vagina and in the nasopharynx of patients presenting with toxic shock syndrome. This explains the clear association between toxic shock syndrome and the use of tampons in menstruating women or ear, nose, and throat surgery in non-menstruating children.
Streptococcal superantigens are responsible for the other form of the disease known as streptococcal toxic shock syndrome. Group A invasive streptococcus are more likely to produce these superantigens, hence their association with the development of toxic shock syndrome.
Another important risk factor for toxic shock syndrome in children is the lack of specific antibodies against TSST-1 or streptococcal superantigens. Patients without a proper immune response are more likely to develop recurrent toxic shock syndrome, and the disease might become more invasive.
Clinical Presentation of Toxic Shock Syndrome in Children
Fever is usually high grade, > 39° C. Common symptoms of staphylococcal toxic shock syndrome include chills, myalgia, malaise, headache, sore throat, muscle tenderness, fatigue, abdominal discomfort, vomiting, diarrhea, altered level of consciousness, confusion, and desquamative skin rash.
Patients with streptococcal toxic shock syndrome might not have a fever. They usually present with severe systolic hypotension, acute respiratory distress syndrome, a generalized desquamative skin rash, and localized soft tissue necrosis.
Patients might also develop myositis or necrotizing fasciitis. Renal impairment and coagulopathy, along with an increased risk of bleeding disorders, are commonly seen in patients with toxic shock syndrome due to group A invasive streptococcus.
Recent medical history can also help differentiate between staphylococcal and streptococcal toxic shock syndrome. Patients with staphylococcal toxic shock syndrome might have a recent history of the use of tampons or skin burns.
On the other hand, patients with streptococcal toxic shock syndrome might develop the condition as a superimposed infection after the eruption of a varicella-related rash.
Gastrointestinal symptoms are more common with staphylococcal toxic shock syndrome, while inflammation of the muscles and an elevated creatinine kinase are more common in streptococcal toxic shock syndrome.
Multi-organ failure manifests as hypotension, acute renal injury, and abnormal liver function, as depicted below.
Multi-organ failure represents the involvement of three organ systems:
- CNS (altered mental status)
Late finding: peeling hands/feet
Diagnostic Workup for Toxic Shock Syndrome in Children
Patients with toxic shock syndrome develop multi-system dysfunction. To diagnose staphylococcal toxic shock syndrome, the patient has to have a fever, a skin rash, hypotension, and desquamation. In addition, three of the following signs of multi-system dysfunction are needed to confirm the diagnosis.
Symptoms of gastrointestinal involvement or severe myalgia, in addition to elevated serum creatinine and serum urea nitrogen levels, suggest acute renal injury. Elevated total bilirubin, AST, and ALT levels indicate a hepatic injury. Thrombocytopenia also occurs in staphylococcal toxic shock syndrome.
Bacteremia is rare in staphylococcal toxic shock syndrome but, if a blood culture was performed, it may be positive for staphylococcus aureus. Other causes of a similar clinical picture, such as Rocky Mountain spotted fever or measles, should be excluded by serologic tests.
Patients with streptococcal toxic shock syndrome are expected to have a similar semiology, but they are more likely to have an elevated creatinine kinase, suggesting myonecrosis. Creatinine levels are usually elevated due to acute kidney injury. Thrombocytopenia and impaired hepatic function are also seen with streptococcal toxic shock syndrome.
A chest X-ray in streptococcal toxic shock syndrome might reveal a characteristic picture of diffuse lung edema and infiltrates typical of acute respiratory distress syndrome. Blood cultures are more likely to be positive with streptococcal toxic shock syndrome than staphylococcal because bacteremia is more common with streptococcal etiology.
Other potential causes of presentation:
- Allergic reaction
- Serum sickness
- Scarlet fever
- Tick-borne illness (RMSF, ehrlichia)
Treatment of Toxic Shock Syndrome in Children
- Examine all post-pubertal females immediately to remove a possible retained tampon, even if there is no history of retention
- Treat all sources of infection (strep throat, drain any abscesses, etc.)
- Supportive care (IV boluses, dopamine, airway support, etc.)
- IVIG may be used in severe cases
Patients with toxic shock syndrome due to extensive burns should be admitted to the burns unit as they are usually hemodynamically unstable. In addition to adequate fluid replacement therapy, proper antibiotic use is also warranted.
Patients with probable or confirmed staphylococcal toxic shock syndrome should undergo a full examination to identify the most likely origin of the infection. Tampons, if found, should be removed and skin abscesses should be drained.
Antibiotic use is then indicated. Nafcillin, oxacillin, or a first-generation cephalosporin are first-line therapies for Staphylococcus aureus infections. If the patient has a methicillin-resistant strain of Staphylococcus aureus, he or she should be switched to vancomycin.
The problem with nafcillin, oxacillin, and cephalosporins is that they are more likely to cause an acute increase in the release of TSST-1 once initiated. Because of this, clindamycin, erythromycin, or rifampin are first-line therapies for staphylococcal toxic shock syndrome.
Streptococcal toxic shock syndrome should be treated with clindamycin to reduce toxin production. Recent studies suggest the combination of clindamycin with penicillin for optimum results with streptococcal toxic shock syndrome. Cefazolin kills faster early in the disease. Unfortunately, mortality remains higher with streptococcal toxic shock syndrome compared to staphylococcal toxic shock syndrome.
Transition to PO cephalexin or clindamycin with stabilization and target any obtained organism. Patients with severe shock might benefit from receiving intravenous immunoglobulins in addition to antibiotic therapy. Intravenous immunoglobulins can be effective when used in the case of superantigens.
Complications of toxic shock syndrome include:
- Renal failure
- Gangrenous/cyanotic extremities
- Neuropsychiatric manifestations, such as memory loss and lack of concentration
- Acute respiratory distress syndrome (ARDS) in 55% of patients, especially in streptococcal type
- Death in 30% of patients